Biogen, Inc. – Strategy, SWOT and Corporate Finance Report
Summary

Biogen, Inc. – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Biogen, Inc. (or ‘the company’), formerly known as Biogen Idec, is a biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of therapies in the areas of hematology, neurology and immunology. The company’s key products include Tecfidera, Tysabri (natalizumab), Avonex (Interferon beta-1a) and Rituxan (rituximab). The company primarily operates in the US and Europe. It is headquartered in Weston, Massachusetts and employed about 7,350 people as of December 31, 2015.

Scope

- Detailed information on Biogen, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Biogen, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Biogen, Inc. including a breakdown and examination of key business segments
- Intelligence on Biogen, Inc.’s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Biogen, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of Biogen, Inc. and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Biogen, Inc. as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers’ businesses better.
- Stay up to date on Biogen, Inc.’s business structure, strategy and prospects.